IDEXX (IDXX) Q3 2026 Earnings Call Transcript
IDEXX (IDXX) reported Q3 2026 earnings with strong demand for diagnostic solutions, including 5.8K premium instrument placements. Revenue grew 10% organically, with EPS at $4.10, up 18%. The company raised full-year revenue guidance to $4.741B-$4.767B and EPS outlook to $14.96-$15.16. Growth was driven by CAG Diagnostics, water, and LPD businesses, with international markets showing double-digit gains. The ezyVet acquisition contributed $5M in revenue and is expected to drive future growth.
How this was made
The 30-second read
Why it matters
IDXX disclosed a guidance raise for full-year revenue and EPS, attributed to strong Q3 organic growth and recurring diagnostics momentum, while also flagging near-term dilution tied to ezyVet acquisition costs.
Market read
Traders can update models and positioning based on the raised full-year revenue and EPS ranges and the stated dilution and margin impacts from ezyVet.
What to watch
Investors may scrutinize the sustainability of premium instrument placements and the ramp rate of InVue Dx recurring revenue, plus how ezyVet costs flow through operating margins.
Background
The article is an IDEXX Q3 2026 earnings call transcript covering operating performance, segment growth, and an updated full-year outlook including ezyVet acquisition contributions.
Ticker impact
IDXX raised its full-year revenue range to $4.741B-$4.767B and EPS outlook to $14.96-$15.16 after Q3 results and ezyVet-related updates.
Likely positive bias as the market prices in higher revenue and EPS outlook, partially offset by dilution expectations tied to ezyVet.
The transcript explicitly updates full-year revenue and EPS ranges, cites strong organic growth drivers, and acknowledges near-term dilution related to the ezyVet acquisition costs.
Market effects
Signals continued strength in veterinary diagnostics demand and recurring consumables/reference lab growth, supportive for the broader animal health diagnostics theme.
Highlights US and international organic growth (including double-digit international CAG recurring revenue growth), suggesting demand resilience across regions.
Reinforces global veterinary diagnostic utilization trends and the monetization of installed-base instruments and software platforms.
Counterpoint
The EPS outlook increase is accompanied by near-term dilution from ezyVet, so the market may focus on margin and dilution trajectory rather than the headline EPS range.
Key entities
- companyIDEXX Laboratories
Veterinary diagnostics and software company providing Q3 results and updated full-year revenue and EPS outlook, including ezyVet-related updates.
- acquisitionezyVet
AI-native ambient listening and clinical workflow software provider acquired by IDEXX, with an annualized revenue run rate cited in the transcript.
